A mid-sized EU pharmaceutical company sought to track global threats to their psychiatric portfolios. They needed accurate and recurring risk assessments of emerging competitors based on clinical success and product overlap.

Opus Strategy’s objective was to provide the client with timely and actionable competitive intelligence. Outputs included:

• Led strategic workshop to promote internal consensus around competitive threats for two psychiatric indications
• Generated biannual market landscape reports with detailed risk assessments, executive summary of key market updates, anticipated milestones, product and trial profiles and pipeline overview
• Created tailored commentary around impact of emerging news for bi-weekly newsletters

• Fostered internal consensus around the relative threat of emerging competitors and informed product positioning and strategic decisions
• Provided early warning alerts around novel competitor advances
• Opus Strategy’s analysis led to a multi-year collaboration including an expansion into other therapeutic areas